Comparative immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines: results of a pilot clinical study [PDF]
Heliyon, 2023 Introduction: There are few comparative studies on efficiency of broad range COVID19 vaccination strategy. This pilot aims to describe the effect of mixed COVID19 vaccination on vaccination adoption and subsequent total immunity, Conducted in Republic of
Igor Stoma +4 more
doaj +2 more sources
Vaccines, 2022 In the present study, antibody and T cell-mediated immune responses elicited by BBIBP-CorV and BNT162b2 vaccines were compared 6 months after the two-dose immunization of healthy individuals.
Zsolt Matula +6 more
doaj +2 more sources
Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial [PDF]
Signal Transduction and Targeted Therapy, 2022 The increased coronavirus disease 2019 (COVID-19) breakthrough cases pose the need of booster vaccination. We conducted a randomised, double-blinded, controlled, phase 2 trial to assess the immunogenicity and safety of the heterologous prime-boost ...
Nawal Al Kaabi +37 more
doaj +2 more sources
Effectiveness of the BBIBP-CorV vaccine in preventing infection and death in health care workers in Peru 2021 [PDF]
Travel Medicine and Infectious Disease, 2023 Background: During 2021, Peru started the vaccination against SARS-CoV-2 using the BBIBP-CorV inactivated virus vaccine for health care workers (HCW).
Javier Silva-Valencia +2 more
exaly +3 more sources
Vaccines, 2022 Many available SARS-CoV-2 vaccines demonstrated good humoral response, but studies directly comparing their immunogenicity in the general population are lacking.
Vladimir Petrović +4 more
doaj +2 more sources
Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2 [PDF]
Frontiers in Medicine, 2023 BackgroundVaccination has proven the potential to control the COVID-19 pandemic worldwide. Although recent evidence suggests a poor humoral response against SARS-CoV-2 in vaccinated hematological disease (HD) patients, data on vaccination in these ...
Enikő Szabó +19 more
doaj +4 more sources
Vaccines, 2022 Fifty five percent of the Pakistani population is still unvaccinated with the two-dose protocol of COVID-19 vaccines. This study was undertaken to determine the seroconversion rate and antibody titers following the two-dose BBIBP-CorV protocol, and to ...
Javeria Aijaz +8 more
doaj +2 more sources
Monitoring and active surveillance of adverse events following the booster dose of AZD1222 vaccine in people vaccinated with Sinopharm BBIBP-CorV: a cohort study [PDF]
BMC Public HealthBackground Given the limited evidence on the side effects of AZD1222 booster in individuals previously vaccinated with Sinopharm BBIBP-CorV, we conducted a cohort event monitoring study to capture adverse events in those receiving AZD1222 booster doses ...
Shahin Soltani +10 more
doaj +2 more sources
Clinical characteristics, outcomes, and risk factors of SARS-CoV-2 breakthrough infections among 572 fully vaccinated (BBIBP-CorV) hospitalized patients [PDF]
Heliyon, 2023 Background: Breakthrough infections have been widely reported in vaccinated individuals. However, the clinical characteristics, outcomes, and risk factors of SARS-CoV-2 breakthrough infections among fully vaccinated (BBIBP-CorV) hospitalized patients ...
Yihuang Liu +3 more
doaj +2 more sources
Vaccine: X, 2023 Background: The inactivated virus vaccine, BBIBP-CorV, was principally distributed across low- and middle-income countries as primary vaccination strategy to prevent poor COVID-19 outcomes.
Stephanie Montero +11 more
doaj +2 more sources